A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial

A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial

<p>Abstract</p> <p>Background</p> <p>Patients with acute myeloid leukemia (AML) are often neutropenic as a result of their disease. Furthermore, these patients typically experience profound neutropenia following induction and/or consolidation chemotherapy and this may r...

Full description

Bibliographic Details
Main Authors:	Noga Stephen J, Thomas Xavier, Lazzarino Mario, Herrmann Richard, Kassis Jeannine, Szer Jeffrey, Sierra Jorge, Baker Nigel, Dansey Roger, Bosi Alberto
Format:	Article
Language:	English
Published:	BMC 2008-07-01
Series:	BMC Cancer
Online Access:	http://www.biomedcentral.com/1471-2407/8/195

Similar Items

CHEMOTHERAPY-INDUCED NEUTROPENIA IN HIV POSITIVE PATIENTS WITH LYMPHOMA: COMPARISON OF PEGFILGRASTIM WITH DAILY FILGRASTIM ADMINISTRATION.
by: Luciana Teofili, et al.
Published: (2012-01-01)

CHEMOTHERAPY-INDUCED NEUTROPENIA IN HIV POSITIVE PATIENTS WITH LYMPHOMA: COMPARISON OF PEGFILGRASTIM WITH DAILY FILGRASTIM ADMINISTRATION.
by: Luciana Teofili, et al.
Published: (2012-10-01)

Effectiveness of cytopenia prophylaxis for different filgrastim and pegfilgrastim schedules in a chemotherapy mouse model
by: Markus Scholz, et al.
Published: (2008-12-01)

Comparing the efficacy and side-effects of PDLASTA® (Pegfilgrastim) with PDGRASTIM® (Filgrastim) in breast cancer patients: a non-inferiority randomized clinical trial
by: Safa Najafi, et al.
Published: (2021-04-01)

A randomized, non-inferiority study comparing efficacy and safety of a single dose of pegfilgrastim versus daily filgrastim in pediatric patients after autologous peripheral blood stem cell transplant.
by: Simone Cesaro, et al.
Published: (2013-01-01)

Neutrophilic eccrine hidradenitis secondary to pegfilgrastim in a patient with synovial sarcoma
by: Neha Puar, et al.
Published: (2019-03-01)

Treatment of natalizumab‐associated PML with filgrastim
by: Dusan Stefoski, et al.
Published: (2019-05-01)

Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF)
by: Naeim Arash, et al.
Published: (2013-01-01)

Innovator Filgrastim versus Generic Filgrastim in Hematopoietic Stem Cell Transplantation Mobilization
by: Sadik Husian, et al.
Published: (2021-09-01)

Localized Pegfilgrastim-induced Neutrophilic Dermatosis with Tissue G-CSF Expression: A Mimicker of Sweet’s Syndrome
by: Toshio Ichiki, et al.
Published: (2019-04-01)

Immunogenicity and safety of a proposed pegfilgrastim biosimilar MSB11455 versus the reference pegfilgrastim Neulasta® in healthy subjects: A randomized, double‐blind trial
by: Chris Wynne, et al.
Published: (2020-04-01)

Immunogenicity Assessment of Pegfilgrastim in Patients with Breast Cancer
by: Yu. V. Medvedev, et al.
Published: (2020-05-01)

Biosimilars in the management of neutropenia: focus on filgrastim
by: Caselli D, et al.
Published: (2016-02-01)

Biosimilar filgrastim vs filgrastim: a multicenter nationwide observational bioequivalence study in patients with chemotherapy-induced neutropenia
by: Sevinç A, et al.
Published: (2018-01-01)

Efficacy and safety of two pegfilgrastim biosimilars: Tripegfilgrastim and pegteograstim
by: Ka‐Won Kang, et al.
Published: (2020-09-01)

Incidence of febrile neutropenia during chemotherapy among patients with nonmyeloid cancer receiving filgrastim vs a filgrastim biosimilar
by: Schwartzberg LS, et al.
Published: (2018-09-01)

Clozapine re-challenge under the cover of Filgrastim
by: R Gopalakrishnan, et al.
Published: (2013-01-01)

Safety of Pegfilgrastim (Neulasta) in Patients with Sickle Cell Trait/Anemia
by: Pashtoon Murtaza Kasi, et al.
Published: (2013-01-01)

The Use of Filgrastim in Patients with Hodgkin Lymphoma Receiving ABVD
by: Adam F. Binder, et al.
Published: (2017-10-01)

Pharmacodynamics, safety, and immunogenicity of Pelmeg®, a pegfilgrastim biosimilar in healthy subjects
by: Hendrik Wessels, et al.
Published: (2019-10-01)

EFFECTIVENESS AND SAFETY OF FILGRASTIM BIOANALOGUE IN TREATMENT AND PROPHYLAXIS OF GRANULOCYTOPENIA IN CHILDREN
by: A.A. Maschan, et al.
Published: (2010-01-01)

Acute Myocardial Infarction Caused by Filgrastim: A Case Report
by: Cemil Bilir, et al.
Published: (2012-01-01)

EFFECTIVENESS AND SAFETY OF FILGRASTIM BIOANALOGUE IN TREATMENT AND PROPHYLAXIS OF GRANULOCYTOPENIA IN CHILDREN
by: A.A. Maschan, et al.
Published: (2010-01-01)

Biomarker Supervised G-CSF (Filgrastim) Response in ALS Patients
by: Siw Johannesen, et al.
Published: (2018-11-01)

Effect of Filgrastim on adult male rats’ fertility and reproductive performance
by: Sara Mohamed Saber, et al.
Published: (2021-04-01)

Development and certification of an industrial reference standard for determination of filgrastim activity
by: E. V. Motuzova, et al.
Published: (2018-02-01)

Efficacy and safety of RGB-02, a pegfilgrastim biosimilar to prevent chemotherapy-induced neutropenia: results of a randomized, double-blind phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving chemotherapy
by: Zsuzsanna Kahan, et al.
Published: (2019-02-01)

A Budget impact analysis of pegfilgrastim biosimilar in the treatment of febrile neutropenia in Italy
by: Roberto Ravasio, et al.
Published: (2020-03-01)

Prophylaxis against febrile neutropenia with pegfilgrastim in Italy: a budget impact analysis
by: Giovanni Rosti, et al.
Published: (2011-09-01)

Drug-induced aortitis of the subclavian artery caused by pegfilgrastim: a case report
by: Hikari Jimbo, et al.
Published: (2021-08-01)

Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of Pelmeg®, a pegfilgrastim biosimilar in healthy subjects
by: Karsten Roth, et al.
Published: (2019-10-01)

Lenograstim and filgrastim in the febrile neutropenia prophylaxis of hospitalized patients: efficacy and cost of the prophylaxis in a retrospective survey
by: Innocenti R, et al.
Published: (2018-12-01)

A phase III, randomized, non-inferiority study comparing the efficacy and safety of biosimilar filgrastim versus originator filgrastim for chemotherapy-induced neutropenia in breast cancer patients
by: Roberto Hegg, et al.

Chemomobilization with cyclophosphamide and filgrastim in multiple myeloma patients following lenalidomide treatment
by: Gerfen, Ashlee
Published: (2012)

Chemomobilization with Cyclophosphamide and Filgrastim in Multiple Myeloma Patients Following Lenalidomide Treatment
by: Gerfen, Ashlee, et al.
Published: (2012)

Use and effectiveness of pegfilgrastim prophylaxis in US clinical practice:a retrospective observational study
by: Derek Weycker, et al.
Published: (2019-08-01)

Lenograstim and filgrastim in the febrile neutropenia prophylaxis of hospitalized patients: efficacy and cost of the prophylaxis in a retrospective survey [Corrigendum]
by: Innocenti R, et al.
Published: (2019-02-01)

Efficacy and safety analysis of once per cycle pegfilgrastim and daily lenograstim in patients with breast cancer receiving adjuvant myelosuppressive chemotherapy FEC 100: a pilot study
by: Rossi L, et al.
Published: (2013-11-01)

Analysis of ANC Levels after Filgrastim Therapy in Acute Leukemia Children with Neutropenia
by: Reta Anggraeni Widya, et al.
Published: (2021-01-01)

Filgrastim Induced Severe Leukocytosis in Sepsis-Associated Leukopenia: A Case Repor
by: Foroud Shahbazi, et al.
Published: (2019-07-01)